Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Terumo Receives FDA Go-Ahead To Start Trial As Part Of U.S./Japan Pilot

This article was originally published in PharmAsia News

Executive Summary

Japanese device maker Terumo on May 12 announced it had received conditional U.S. FDA approval to begin enrollment for a U.S. clinical trial of its Misago superficial femoral artery stent

You may also be interested in...



U.S., Japan Regulators Begin Collaborative Review Pilot With Femoral Stents

FDA and Japanese regulators recently began to work together to review two devices - one U.S.-manufactured, one Japanese-made - that are part of a new pilot program intended to model how products can achieve faster market entry in both countries

U.S.-Japan Pilot Project In Pre-Market Collaboration Begins Soon

FDA and its Japanese counterpart will soon name the two devices - one American, one Japanese - they will use in a new pilot project that could lead to faster market access for products destined for both markets, according to CDRH's Carole Carey

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel